Larvol Delta - Neurimmune-and-TVM-Capital-Life-Science-announce-the-initiation-of-ALS-Pharmas-phase-1-study-of-AP101-for-the-treatment-of-ALS

AP-101 - AL-S Pharma

https://www.prnewswire.com/news-releases/neurimmune-and-tvm-capital-life-science-announce-the-initiation-of-al-s-pharmas-phase-1-study-of-ap-101-for-the-treatment-of-als-300939318.html

Oct 16, 2019

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev